M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer and Interim Head, Janssen R&D. “We remain focused on advancing our differentiated pipeline, improving the lives of millions of patients and developing new modalities in areas with the greatest unmet medical need...
M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer and Interim Head, Janssen R&D. “We remain focused on advancing our differentiated pipeline, improving the lives of millions of patients and developing new modalities in areas with the greatest unmet medical need...
A data pipeline driven by an analytics enginedesigned to support meaningful data collection in clinical trials to construct a unique picture for each child, resulting in dynamic profiles for respondents and ultimately output in clinical trials. ...
Stock Recap #PipelineProspector | All News #Library Janssen-Cilag`s Biologic Stelara (ustekinumab) Receives Approval in the U.S. 18 Mar 2024 // FDA Janssen`s Biologic Tecvayli (teclistamab) Receives Approval in the U.S. 20 Feb 2024 // FDA Janssen`s Biologic Talvey (talquetamab-tg...
lifeiteng's VALL-E for training pipeline and model architecture design. WeNet, Whisper, ContentVec, and RawNet3 for pretrained models and inference code. HiFi-GAN for GAN-based Vocoder's architecture design and training strategy. Encodec for well-organized GAN Discriminator's architecture and bas...
this represents a strong growth year-over-year reflecting significant patient demand and the work the company has done to increase manufacturing capacity. WhileCARVYKTI’s sales in Q3 and Q4 2022 remained the same with USD 55 and 54 million. Even in Q1 of 2023, ABECMA generated revenue ofUSD...
Johnson & Johnson Neil Davie, Ph.D. Head, Late Development Cardiovascular, Metabolism & Pulmonary Hypertension Ruxandra Draghia-Akli, M.D., Ph.D. Global Head Johnson & Johnson Global Public Health R&D Janssen Research & Development Penny Heaton, M.D. ...
2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filin...
underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200...
07 Sep 2022 (Phase-III development is ongoing in USA and Europe (Johnson & Johnson pipeline, September 2022) 25 Apr 2022 Janssen Vaccines and Prevention B.V completes a phase-II clinical trial in HIV infections (Prevention) in USA (IM) (NCT02788045) 01 Mar 2022 Janssen Vaccines & Preve...